Show simple item record

dc.contributor.authorSimpson, Colin R
dc.contributor.authorKerr, Steven
dc.contributor.authorKatikireddi, Srinivasa Vittal
dc.contributor.authorMcCowan, Colin
dc.contributor.authorRitchie, Lewis D
dc.contributor.authorPan, Jiafeng
dc.contributor.authorStock, Sarah J
dc.contributor.authorRudan, Igor
dc.contributor.authorTsang, Ruby S M
dc.contributor.authorde Lusignan, Simon
dc.contributor.authorHobbs, F D Richard
dc.contributor.authorAkbari, Ashley
dc.contributor.authorLyons, Ronan A
dc.contributor.authorRobertson, Chris
dc.contributor.authorSheikh, Aziz
dc.date.accessioned2022-11-21T17:12:01Z
dc.date.available2022-11-21T17:12:01Z
dc.date.issued2022-08-15
dc.identifier.citationSimpson , C R , Kerr , S , Katikireddi , S V , McCowan , C , Ritchie , L D , Pan , J , Stock , S J , Rudan , I , Tsang , R S M , de Lusignan , S , Hobbs , F D R , Akbari , A , Lyons , R A , Robertson , C & Sheikh , A 2022 , ' Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland ' , Nature Communications , vol. 13 , 4800 . https://doi.org/10.1038/s41467-022-32264-6en
dc.identifier.issn2041-1723
dc.identifier.otherPURE: 219622789
dc.identifier.otherPURE UUID: 5ef10dfa-2e7f-4b57-8e16-a2c6c3e3d975
dc.identifier.otherPubMed: 35970827
dc.identifier.otherPubMedCentral: PMC9377297
dc.identifier.otherScopus: 85135990893
dc.identifier.urihttps://hdl.handle.net/2164/19574
dc.descriptionAcknowledgements EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care. FDRH acknowledges part support as Director of the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, and Theme Lead of the NIHR OUH BRC. We thank Dave Kelly from Albasoft Ltd for his support with making primary care data available and Frances Burns, Mathhew Thankur, Wendy Inglis-Humphrey, Vicky Hammersley, Dom Balharry and Laura Brook, Morag Edwards and Laura Gonzalez Rienda for their support with project management and administration. We thank the EAVE II Public Advisory Group. Our thanks to Prof. Jenni Quint, Prof. Rustam Al-Shahi Salman and Dr. Quentin Hill for their help with reviewing code lists.en
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofNature Communicationsen
dc.rightsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAdulten
dc.subjectBNT162 Vaccineen
dc.subjectCOVID-19/epidemiologyen
dc.subjectCOVID-19 Vaccines/adverse effectsen
dc.subjectHumansen
dc.subjectProspective Studiesen
dc.subjectPurpura, Thrombocytopenic, Idiopathic/epidemiologyen
dc.subjectScotlanden
dc.subjectThromboembolism/epidemiologyen
dc.subjectVaccination/adverse effectsen
dc.subjectR Medicine (General)en
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/R008345/1en
dc.subjectOtheren
dc.subjectMC_PC_19004en
dc.subject.lccR1en
dc.titleSecond-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotlanden
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1038/s41467-022-32264-6
dc.identifier.vol13en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record